Key Takeaways From the CARTITUDE-4 Trial in Multiple Myeloma
Binod Dhakal, MD, MS, discusses the key takeaways from the CARTITUDE-4 trial which were presented at the 2024 International Myeloma Society Annual Meeting.
Binod Dhakal, MD, MS, assistant professor of medicine in the Division of Hematology and Oncology at the Medical College of Wisconsin, discusses the key takeaways from the CARTITUDE-4 (NCT04181827) trial which were presented at the 2024 International Myeloma Society Annual Meeting.
According to updated results from the trial, ciltacabtagene autoleucel (cilta-cel; Carvykti) reduced the risk of death by 45% vs standard of care in this patient population. Additionally, the follow-up data at 33 months highlights 2 key benefits of the treatment: a significant overall survival advantage and an impressive, still-unreached median progression-free survival (PFS), suggesting effectiveness beyond 3 years.
Additionally, the regimen shows a favorable risk-benefit profile, with minimal neurotoxicities. While secondary primary malignancies were noted in 10%-12% of patients, hematological malignancies were low, at around 3%.
Transcription:
0:14 | [First], what we saw at longer follow-up is that we are already seeing, at 33 months, an overall survival benefit, which very few regimens in this space have achieved. That is probably the most important takeaway. The other important takeaway is the median PFS has not been reached at 33.6 months. So, that means we are anticipating the median PFS to be much longer than 3 years. [This suggests] it is probably one of the most effective regimens in this space.
0:42 | Number 3, one of the concerns is about some of the delayed toxicities that could happen with longer follow-up. We did not see [any significant] neurotoxicities…So, overall, the risk-benefit profile strongly favors cilta-cel. One of the other things that to note is about the secondary primary malignancies. The secondary primary malignancy is about 10% to 12% in the cilta-cel arm. Specifically, hematological malignancies occurred in about 3%, which is relatively low. This is something to be aware of and to discuss with patients when we offer this treatment, in terms of risks and benefits. Overall, this data [indicates] a very good result for patients.
